We saw no significant relationship between concentrations of a1-AT and specific hyperlipidemias.
However, a higher than normal proportion of unusual phenotypes cccurred in the study group (see Table 1 ). These are anodal variants and are currently thought to be the L-variant previously described by Fagerhol and Cox (1).
These preliminary data suggest that patients with hyperlipidemia may have an increased frequency of unusual a1-AT phenotypes. Further investigation should reveal whether, in large families, this phenotype segregates with that of a particular hyperlipidemia. The method is sensitive: the detection limit (2 SD from zero standard, n = 10) is 4.5 g/L, but could be increased to 0.6 pg/L by increasing the incubation period (180 mm) and substrate concentration and by diluting the standards and the enzyme conjugate. The high reproducibility of the coated tubes (CV for zero dose, 1.2-2.8%) allowed good precision. For cortisol concentrations of 62.7, 163.9, and 370 /.Lg/L in serum, CVs (n = 10) were 6.9,4.5, and 5%, respectively, and between-assay CVs (n = 8) were 7.1,3.5, and 6.5%. Analytical recovery of cortisol (20-160 g/L) added to three different sera (endogenous cortisol 14 to 162 tg/L) was 101.3 (SD 6.8)%. Results of dilution tests and assays of reference sera also agreed closely with the expected values, verifying the accuracy of the assay. Cross reactivity (50% displacement) with other hormones was: prednisolone 84.9%, 11-deoxycortisol 31.4%, cortisone 6.5%, dexamethasone 1.5%, 17-hydroxyprogesterone 0.9%, corticosterone 0.6%, deoxycorticosterone 0.03%, and progesterone, estrone, and estriol all <0.03%. Finally, results correlated well (r = 0.96, n = 57, cortisol concentrations ranging from 10 to 400 gfL) with those by a direct RIA ("Coat-A-Count"; Diagnostic Products Corp.).
Except for the indicator reaction step, the assay procedure is similar to that of the direct coated-tube RIA method.
The enzymatic tracer, prepared by the mixed anhydride method (J Biol Chem 1957;228:713-27) with modifications, is stable for at least six months as a refrigerated ready-touse working solution and for one year in the frozen concentrated form. Only one working reagent, the substrate solution, has to be freshly prepared for each run, by simply reconstituting lyophilized o-phenylenediamine with hydrogen peroxide solution.
